Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dianthus Therapeutics ( (DNTH) ) has shared an update.
On March 10, 2026, Dianthus Therapeutics, Inc. entered into an underwriting agreement with a syndicate of investment banks to launch a public offering of 7,313,582 shares of common stock at $81.00 per share and pre-funded warrants equivalent to 402,468 shares at $80.999 per share. The underwriters exercised in full a 30-day option on March 11, 2026 to purchase an additional 1,157,407 shares at the public offering price, less underwriting discounts and commissions.
The offering, conducted under an effective shelf registration and related SEC filings, is expected to close on March 12, 2026 and generate approximately $673.5 million in net proceeds for Dianthus Therapeutics after fees and expenses. The deal structure, including exercise caps on the pre-funded warrants and standard indemnification provisions for the underwriters, significantly bolsters the company’s capital base and financial flexibility while managing ownership concentration among investors.
The most recent analyst rating on (DNTH) stock is a Hold with a $92.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.
Spark’s Take on DNTH Stock
According to Spark, TipRanks’ AI Analyst, DNTH is a Neutral.
The score is primarily constrained by weak and worsening financial performance (widening losses and rising cash burn), partially offset by a strong balance sheet. Technicals are strong but appear overextended, while valuation lacks support due to losses and no dividend. A positive corporate update around Phase 3 progress and substantial cash runway provides a meaningful offset.
To see Spark’s full report on DNTH stock, click here.
More about Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic products, with its shares registered and sold in the U.S. capital markets. The company raises funding through public equity offerings of common stock and related securities to support its operations and strategic initiatives.
Average Trading Volume: 943,068
Technical Sentiment Signal: Buy
Current Market Cap: $3.82B
Learn more about DNTH stock on TipRanks’ Stock Analysis page.